Lanfranco Fattorini

Istituto Superiore di Sanità — Italy

Medicine · Health Sciences

36h-index4.6kcitations133works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Tuberculosis Research and Epidemiology(106), Mycobacterium research and diagnosis(94), Antibiotic Resistance in Bacteria(24), Infectious Diseases and Tuberculosis(15), Cancer therapeutics and mechanisms(11)

Publications133 total

Activity of combinations of bactericidal and bacteriostatic compounds in Mycobacterium abscessus-infected mice: an overview
Frontiers in Microbiology·2025· 2 citedOpen Access
Epidemiology and drug susceptibility of nontuberculous mycobacteria (NTM) in Italy in 2016-2020.
PubMed·2023· 4 citedOpen Access
Eradication of Drug-Tolerant Mycobacterium tuberculosis 2022: Where We Stand
Microorganisms·2023· 6 citedOpen Access
Eradication of Drug-Tolerant Mycobacterium tuberculosis 2022: Where We Stand
Preprints.org·2023· 4 citedOpen Access
Activity of Drug Combinations against Mycobacterium abscessus Grown in Aerobic and Hypoxic Conditions
Microorganisms·2022· 15 citedOpen Access
Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment
European Respiratory Journal·2022· 35 citedOpen Access
Mycobacterium tuberculosis and SARS-CoV-2 Coinfections: A Review
Frontiers in Microbiology·2022· 36 citedOpen Access
The Antimalarial Mefloquine Shows Activity against Mycobacterium abscessus, Inhibiting Mycolic Acid Metabolism
International Journal of Molecular Sciences·2021· 9 citedOpen Access
Moxifloxacin Activates the SOS Response in Mycobacterium tuberculosis in a Dose- and Time-Dependent Manner
Microorganisms·2021· 23 citedOpen Access
Bacterial coinfections in COVID-19: an underestimated adversary.
PubMed·2020· 105 cited
Pilot Study on non-tuberculous mycobacteria infections in Italy
European Journal of Public Health·2020· 1 citedOpen Access
Use of probiotics in medical devices applied to some common pathologies.
PubMed·2020· 4 cited
Drug Resistance Mechanisms in Tuberculosis
2020· 2 citedOpen Access
Drug-Resistant Tuberculosis 2020: Where We Stand
Applied Sciences·2020· 89 citedOpen Access
Revisiting problems and solutions to decrease Mycobacterium tuberculosis pyrazinamide false resistance when using the Bactec MGIT 960 system.
PubMed·2019· 6 cited
A rapid unravelling of mycobacterial activity and of their susceptibility to antibiotics
Apollo (University of Cambridge)·2019· 4 citedOpen Access
The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH
Antimicrobial Agents and Chemotherapy·2019· 18 citedOpen Access
A Rapid Unraveling of the Activity and Antibiotic Susceptibility of Mycobacteria
Antimicrobial Agents and Chemotherapy·2019· 30 citedOpen Access
Clofazimine: A useful antibiotic for drug-resistant tuberculosis
Biomedicine & Pharmacotherapy·2018· 77 cited
Activity of DNA-targeted C8-linked pyrrolobenzodiazepine–heterocyclic polyamide conjugates against aerobically and hypoxically grown Mycobacterium tuberculosis under acidic and neutral conditions
The Journal of Antibiotics·2018· 4 cited
page 1 of 7Next →

Frequent Co-authors

Graziella Orefici(23), Federico Giannoni(18), Elisabetta Iona(17), Manuela Pardini(14), Marco R. Oggioni(8), Giovanni Piccaro(8), Alessandro Mustazzolu(8), Lara Brunori(7), Germano Orrù(6), Roberto Nisini(6), Sabine Rüsch–Gerdes(5), Francis Varaine(5), Stefan Niemann(5), Dejiang Tan(5), Raffaela Teloni(5), Gianfranco Amicosante(4), Maria Cristina Gagliardi(4), Claudio Piersimoni(4), Francesca Meacci(4), Giovanni Battista Migliori(3)